MARKET

TCDA

TCDA

Tricida
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.11
+0.55
+1.64%
Opening 11:00 01/29 EST
OPEN
33.66
PREV CLOSE
33.56
HIGH
34.11
LOW
33.18
VOLUME
25.26K
TURNOVER
--
52 WEEK HIGH
44.30
52 WEEK LOW
19.43
MARKET CAP
1.32B
P/E (TTM)
-10.8275
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TCDA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TCDA News

  • Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference
  • Business Wire.01/07 18:59
  • Did Tricida, Inc. (NASDAQ:TCDA) Insiders Buy Up More Shares?
  • Simply Wall St..12/24/2019 16:55
  • Insider Weekends: Third Insider Of Expedia Buys Shares
  • Seeking Alpha - Article.12/17/2019 03:16
  • The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win
  • Benzinga.12/12/2019 12:38

More

Industry

Biotechnology & Medical Research
+0.09%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About TCDA

Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.
More

Webull offers Tricida Inc (TCDA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.